Optimising the dosage of ready-to-use therapeutic food in children with severe acute malnutrition and severe underweight: secondary analysis of the OptiMA-DRC trial.



C. Cazes<sup>1</sup>, R. Alitanou<sup>2</sup>, K. Phelan<sup>3</sup>, V. Hubert<sup>2</sup>, B. Kalenga Tshiala<sup>4</sup>, A. Briend<sup>5,6</sup>, S. Shepherd<sup>2</sup>, R. Becquet1<sup>1</sup>

<sup>1</sup>University of Bordeaux, Bordeaux, France; <sup>2</sup>The Alliance for International Medical Action, Dakar, Senegal; <sup>3</sup>The Alliance for International Medical Action, Paris, France; <sup>4</sup>Ministry of Health, Kinshasa, Democratic Republic of the Congo; <sup>5</sup>University of Copenhagen, Frederiksberg, Denmark; <sup>6</sup>Tampere University, Tampere, Finland

#### Introduction


Children under five with multiple severe anthropometric deficits have the highest risk of death (1). Prior studies indicate that children cumulating wasting and stunting are also underweight (2) and that wasted children with severe underweight are an especially vulnerable group (3). We sought to assess whether tapering the dosage of ready-to-use therapeutic food (RUTF) according to the OptiMA strategy would compromise the anthropometric recovery of the most vulnerable children aged 6-59 months compared with standard RUTF dosage. We also identified factors associated with recovery of acute malnutrition within 16 weeks.

## Methods

- Secondary data analysis of an individually non-inferiority randomised controlled trial in the Democratic Republic of Congo (4).
- Standard arm: RUTF standard dosage (175-200 kcal/kg/j)
- OptiMA arm: RUTF dosage from 175-200 to 75 kcal/kg/day in average as weight and MUAC increased.
- Generalised additive mixed-effects models adjusted for age and using hierarchical random effects on individuals, by study arm to represent the 25-week anthropometric curves of children accumulating a weight-for-age (WAZ) z score <-3 and mid-upper arm circumference (MUAC) <115 mm (n=208).
- Multivariate logistic regression on recovery (i.e. MUAC>125mm and WHZ>-2 without oedema for 16 days within 16 weeks), in children with MUAC<115mm at inclusion (n=284).

### Results


Figure 1: Panel of modelled adjusted weekly means of MUAC, WHZ WAZ and MUAC, weight cumulated gain through 6-month by randomisation groups (n=208, 3065 follow-up visits)



**Growth curves in Optima and standard groups similar for** all parameters over the 6-month follow-up with a median overall ration of RUTF distributed of 112 sachets and 189 sachets, in the OptiMA and standard arms, respectively (p<0.0001).

Figure 2: Factors associated with nutritional recovery within 16 weeks among in children included in OptiMA-DRC trial with MUAC<115 at baseline (n=284)\*

Higher WAZ at inclusion and absence of hospitalisation positively associated while living more than 14km from health centre negatively associated with recovery within 16 weeks, whatever arm, sex, age, MUAC, WHZ at inclusion.



# Conclusion

This secondary analysis of the OptiMA-DRC trial suggests that reducing the dosage of RUTF as weight and MUAC increase is safe for children accumulating severe anthropometric deficits.

Ethics Approved by the National Health Ethics Committee, DRC, and by the Ethics Evaluation Committee of Inserm, the French National Institute for Health and Medical Research (Paris, France).

# References

1. Mac Donald et al. 2013; *Am Jour of Nut*, 97(4), 896–901... 2. Thurstans et al., 2021; Maternal & Child Nutrition, 18, e13246 3. Odei Obeng-Amoako et al., Matern Child Nutr. 2023; 19:e13434. 4. Cazes et al., 2023; eClinicalMedecine, 2023;58: 101878.

Acknowledgments We are indebted to the participants, the staff of the MoH and the ALIMA operational team, the community health workers. We finally warmly thank the Innocent Foundation and the No Wasted Lives Coalition for their support.

